
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at adding a drug called atezolizumab to cabozantinib for kidney cancer.
It is open to people with kidney cancer that has spread to another part of the body or to the surrounding tissue. And it isn’t possible to remove it with surgery.
Cabozantinib is a treatment you might have if your kidney cancer has spread to another part of your body. This is advanced kidney cancer. Cabozantinib is a type of cancer growth blocker. It stops signals that cancer cells use to divide and grow.
Atezolizumab is an immunotherapy. It helps the to find and kill cancer cells. Researchers want to find out if adding it to cabozantinib slows cancer growth. But they aren’t sure so want to find out more.
Having atezolizumab and cabozantinib together is a new treatment. In this trial some people have atezolizumab and cabozantinib. And some have cabozantinib on its own.
The main aims of the trial are to:
The following bullet points are a summary of the entry conditions for this trial
Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply.
You have had previous treatment for kidney cancer that included:
As well as the above the following can’t apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This phase 3 trial is taking place worldwide. The team need to find 500 people to take part including 30 from the UK.
It is a randomised trial. You are put into a group by a computer. Neither you nor your doctor will be able to decide which group you are in. There are 2 treatment groups.
You have 1 of the following:
Treatment
You have . Each 3 week period is a cycle of treatment.
You have atezolizumab as a drip into a vein. You have this once every 3 weeks.
Cabozantinib is a tablet. You take the tablets once a day. The trial doctor tells you how many to take and when to take them. You must not eat or drink anything for at least 2 hours before taking cabozantinib.
Everyone has treatment for as long as it is working and the side effects aren’t too bad.
Blood and tissue samples
The researchers ask you to give some extra tissue samples. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
You need to agree to give most of the samples to take part in the trial. There are a few you don’t need to agree to if you don’t want to. The team can let you know more about this.
Quality of life
The trial team ask you to fill out a questionnaire:
The questionnaire asks about side effects and how you’ve been feeling. This is called a quality of life study.
You see a doctor and have some tests before you can take part in the trial. These include:
You may also need to give a tissue sample ().
During treatment you see the doctor every 3 weeks for a check up and blood tests. You have atezolizumab in the hospital outpatient department. Each treatment visit takes up to 3 hours.
You have a CT scan or an MRI scan:
You might also need to have bone scan at these time points. The team let you know if this applies to you.
When you finish treatment you see the doctor 1 month later for a check up.
Follow up
The team follow you up every 3 months when you finish treatment. You might see them at a routine hospital appointment or they may call you to see how you are getting on.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Atezolizumab can affect the immune system. It may cause inflammation in different parts of the body. This can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening. If you have any of these side effects tell your doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy. |
The most common side effects of atezolizumab are:
The most common side effects of cabozantinib include:
The trial doctor will talk to you about all the possible side effects of treatment.
We have more information about:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Guy Faust
F. Hoffmann-La Roche Ltd
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”